Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA

Marta Torres-Ferrus1,2, Víctor José Gallardo2, Alicia Alpuente1,2 and Patricia Pozo-Rosich1,2*

Abstract

Background: There is a need to establish which are the more relevant headache-related outcomes that have an impact on our patient’s lives to accurately evaluate treatment response in daily clinical practice.

Objective: The aim of this study was to evaluate the relevance of clinical trial endpoints in clinical real-life disability improvement in response to migraine preventive treatment with OnabotulinumtoxinA.

Methods: This is an observational prospective study. We included patients with chronic migraine fulfilling ICHD-3beta/3 criteria. We prospectively collected data of 8 headache-related and acute medication use endpoints recommended by the Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine. We evaluated their impact on disability improvement after 6 months of treatment with OnabotulinumtoxinA. We defined as a responder in disability, patients with ≥50% MIDAS score reduction after 2 cycles of treatment following PREEMPT protocol. We performed an analysis to measure the impact of improvement in the evaluated outcome measures according to perceived disability in clinical practice.

Results: We included 395 patients (85.1% women, mean age 46.7 ± 12.6 years). Mean headache frequency at baseline was 26.5 ± 5.2 headache days/month. After 6 months, 49.1% of patients were headache-related disability responders. From all outcome measures collected, variables independently associated to disability improvement were headache days reduction ($p = 0.02$) and ≥50% pain intensity reduction ($p = 0.04$). A ≥50% reduction in headache frequency or pain intensity showed similar influence on disability improvement after treatment.

Conclusions: Headache pain intensity is as important as frequency when evaluating the clinical response and impact on patient headache-related disability after migraine preventive treatment with OnabotulinumtoxinA.

Keywords: Migraine, Preventive treatment, Headache, Outcome measures, Effectiveness, Onabotulinumtoxin A

* Correspondence: ppozo@vhebron.net
1Headache and Craniofacial Pain Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
2Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Barcelona, Spain

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Chronic migraine, is a prevalent and highly disabling neurological disease [1]. Suffering recurrent migraine attacks produces an abrupt and non-predictable functional disruption of daily life and entails an overwhelming decrease in the patient’s quality of life with a clear negative impact on a personal, family, working, social and economic level. As neurologists and headache specialists, in the absence of treatments that dramatically change the course of migraine, our main goal when treating a patient with chronic migraine is to recognize and minimize headache-related disability.

OnabotulinumtoxinA is an effective chronic migraine preventive therapy that improves disability by reducing quantifiable outcome measures, as headache frequency, duration or attack intensity [2, 3]. Additional benefits may include an enhancement of response to acute treatment, together with a reduction in acute medication intake [4]. As with other migraine preventive treatments, the use of OnabotulinumtoxinA may decrease visits to outpatient clinics, emergency departments and neuroimaging tests proving to be cost-effective [5, 6]. Hence, all these clinical and economical potential effects should be considered when we evaluate treatment effectiveness. Nowadays, due to the lack of quantifiable biochemical or image-based biomarkers in migraine treatment response evaluation, information taken from clinical interview is still essential. However, we need to establish which are the most relevant headache-related outcomes that have an impact on our patient’s lives to accurately evaluate treatment response in daily clinical practice. An inaccurate evaluation of therapy effect may lead to discontinuation of treatment in patients who could be experiencing a substantial benefit in terms of reduction of disability or vice versa, lead to continuation of a therapy that is not producing the expected improvement increasing unnecessary costs.

Recently published International Headache Society Guidelines for clinical trials of preventive treatment of chronic migraine [7] have set the recommendations on which primary or secondary endpoints should be used. Following these guidelines, the primary endpoint for clinical trials in migraine prevention should be either a change in migraine days; a change in moderate to severe headache days; or responder rate. However, other outcomes frequently used as secondary endpoints in clinical trials (e.g. headache intensity, headache free days, duration of effect, use of acute treatment or headache-related disability) are not just indirect measures of efficacy in real-life clinical setting. An improvement in what we consider secondary outcome measures in clinical trials can have a key impact in headache-related disability reduction and quality of life improvement in our patients. So, in our every-day clinical practice, we need to figure out which of these outcome measures for clinical trials can better evaluate the impact of the preventive treatment on patient’s quality of life.

The aim of this study was to evaluate which outcome measures recommended for clinical trials of chronic migraine preventive treatment have a greater influence and better reflect the response to treatment with OnabotulinumtoxinA in regards to patient’s disability.

Methods

Data collection

This is a prospective observational study. We consecutively included patients with migraine fulfilling the International Headache Disorders Classification 3/3beta criteria [8, 9] from July 2014 to October 2019, who had the indication to start a migraine preventive treatment. We included chronic migraine patients at first-time treatment with OnabotulinumtoxinA [10]. We did not exclude patients with stable dose of concomitant oral preventive medications.

Demographic data, comorbidities and migraine characteristics were collected at baseline and after two cycles of OnabotulinumtoxinA following PREEMPT protocol [11]. We included in the evaluation eight headache-related and acute medication-intake endpoints recommended in the Guidelines for clinical trials [7]: change in headache days, >50% headache days responder rate, change in moderate to severe headache days, >50% moderate-severe headache days responder rate, conversion to episodic migraine, >50% intensity of headache responders rate, acute treatment utilization (number of tablets/month) and conversion of medication overuse to non-medication overuse. Patients recorded in a diary headache frequency (total headache days and moderate-severe headache days) and acute medication used for headache relief. A headache day was defined as any day with headache that lasted at least 4 h, and a moderate-severe headache day was defined as a day with moderate or severe pain that lasted 4 h at least [7]. The baseline evaluation included mean headache frequency and analgesic use during 3 months prior to inclusion and we calculated the percentage reduction of these mentioned categories after the second cycle of OnabotulinumtoxinA (from month 4 to 6). Patients also subjectively rated headache pain intensity reduction compared to baseline in three categories (≥25%, 25–49%, ≥50%). Finally, patients completed the Migraine Disability Assessment (MIDAS scale score and grade) [12].

The MIDAS questionnaire is a widely used validated scale designed to evaluate disability within the last 3 months. The patient evaluates, in a 5-item questionnaire, the reduction in the performance, in days, of work/school, household work, and family/social activities. A score 0–270 is used to indicate the overall level of
disability due to headaches and the final score indicates the level of disability which can be then classified into four categories [12]. Scores on the MIDAS are highly correlated with physician judgments regarding patients’ pain, disability, and need for medical care [13] and changes in the MIDAS score may serve as an endpoint in assessing treatment efficacy [14]. The MIDAS questionnaire may have some advantages over other headache-related disability scales in this study. A proportion of patients treated with OnabotulinumtoxinA may experience a wearing off of the effect during the last weeks the treatment cycle with a clinical worsening [15], so other headache-related disability scales with shorter recall period could underestimate treatment response. In order to focus our interest on change in disability after treatment and evaluate the impact of the other outcome measures on disability, we decided to consider a ≥ 50% MIDAS score reduction as a main treatment response variable in our analysis.

The study was approved by Vall d’Hebron Ethics Committee. All patients gave their written informed consent for data collection.

Statistical analysis
Descriptive and frequency statistics were obtained and comparisons made using the R software version (3.6.1). For nominal variables, measures of frequencies used are counts (n) and percentages (%). For quantitative variables, central tendency used is the mean and the standard deviation (SD) as a measure of dispersion (mean ± SD). Statistical significance for intergroup variables was assessed by Pearson chi-square or Fisher’s exact test for categorical variables, the linear trend chi-square test for ordinal variables and the independent t-test Student’s t test or Mann-Whitney U test for quantitative variables. Paired t-test or Wilcoxon signed rank test were used to assess pre-post changes in numerical variables related to the main treatment effectiveness. McNemar’s test for paired proportions was used for categorical data. Parametric tests were only used when a normal distribution was assumed. Data normality were verified through visual methods (histograms and Q-Q plots) and normality test (Kolmogorov-Smirnov test). From the univariate analysis, significant clinical outcomes measures associated to ≥50% MIDAS score reduction were identified.

A logistic regression analysis with backward elimination approach was performed to identify patients with a ≥ 50% MIDAS score improvement as a main response variable to evaluate migraine preventive treatment. Data was initially partitioned into training and testing sets and a 10-fold cross-validation (10-fold CV) was also performed in order to validate the prediction outcomes of our logistic classifier, assessing the model performance by their accuracy and Cohen’s Kappa. Multicollinearity between potential predictors was assessed with the calculation of correlation matrix and the phi correlation coefficient. Hosmer-Lemeshow test was also computed in order to assess the goodness of fit of the model computed. Finally, a receiver operating characteristic curve (ROC) was performed with the predicted probabilities from the model in order to evaluate its discrimination ability based on disability improvement. The logistic regression analysis and the ROC calculation was performed with the caret (6.0–85) and ROCR (1.0–7) packages of R.

P-values presented are for a two-tailed test and p-values < 0.05 were considered as statistically significant. No statistical power calculation was conducted prior to the study because sample size was based on available data.

Results
We included in the analysis 395 patients (85.1% women, mean age 46.7 ± 12.6 years), that represents the 86.8% of patients that initiated treatment with Onabotulinumtoxin A during de inclusion period (5.9% of patients were excluded due to missing information and 7.3% were lost of follow up). From these, mean headache frequency at baseline was 26.5 ± 5.2 headache days/month and 61.3% (242/395) fulfilled criteria for medication overuse. Table 1 shows main demographic and migraine characteristics at baseline.

After 2 cycles of OnabotulinumtoxinA, 49.1% (194/395) of patients reduced their MIDAS score in ≥50% and were considered disability responders. Table 2 shows the change in all outcome measures evaluated. There was a statistically significant reduction in headache frequency (26.5 ± 5.2 to 15.2 ± 10.1 headache days/month, p < 0.001) with 51.4% (203/395) of patients experiencing a ≥ 50% frequency reduction. Moderate to severe headache days were decreased from 12.7 ± 7.5 to 6.7 ± 6.0 days/month (p < 0.001) and 54.2% (214/395) showed a ≥ 50% reduction in moderate to severe days. The headache pain intensity reduction was rated as ≥50% in 35.8% (141/395) of patients and analgesics intake was cut in half in 60.4% (239/395) of patients. A 52.9% (209/395) of patients improved and shifted from chronic to episodic migraine and 37.5% (148/395) stopped overusing acute headache medication.

Clinical endpoints associated to disability improvement
We did not find statistically significant differences in demographic and basal characteristics between responders and non-responders based on ≥50% in MIDAS score reduction.

In regards to established Guideline preventive treatment trial endpoints shown in Table 2, the univariate analysis revealed that all outcome measures were statistically significantly associated to a response in disability...
Table 1 Baseline Demographics and Migraine Characteristics

|                                | N = 395 |
|--------------------------------|---------|
| Gender (female)                | 85.1%   |
| Age (mean, years ± SD)         | 46.7 ± 12.6 |
| Aura                           | 28.6%   |
| Migraine duration (mean, years ± SD) | 28.6 ± 15.0 |
| Chronification time (mean, years ± SD) | 10.5 ± 9.9 |
| Headache frequency (days/month ± SD) | 26.5 ± 5.2 |
| Moderate-Severe headache frequency (days/month ± SD) | 12.7 ± 7.5 |
| Moderate-Severe headache monthly rate (% ± SD) | 49.0 ± 27.6 |
| Acute treatment (% of use)     | 95.7%   |
| NSAIDs                         | 54.6%   |
| Triptans                       | 46.1%   |
| Other analgesics               | 36.3%   |
| Analgesic use (mean, tablets/month ± SD) | 42.2 ± 42.4 |
| Daily use of analgesic         | 38.7%   |
| Medication overuse             | 61.3%   |
| Stable concomitant preventive treatment (%) | 77.0% |
| Neuromodulators                | 39.2%   |
| Betablockers                   | 14.9%   |
| Antidepressants                | 61.5%   |
| Others                         | 10.6%   |
| MIDAS disability category      |         |
| None                           | 5.6%    |
| Mild                           | 4.8%    |
| Moderate                       | 6.8%    |
| Severe                         | 82.8%   |
| MIDAS score (mean ± SD)        | 82.6 ± 64.6 |

Abbreviations: SD standard deviation, NSAID Nonsteroidal anti-inflammatory drugs, MIDAS Migraine Disability Assessment

Table 2 Change in evaluated clinical outcome measures after treatment

|                                   | All sample (N = 395) | Responders* (N = 194) | No responders (N = 201) | P-value* |
|-----------------------------------|----------------------|------------------------|-------------------------|----------|
| Headache days/month               | −11.3 ± 10.7         | −15.3 ± 10.2           | −7.4 ± 7.3              | <0.0001  |
| Moderate-severe headache days/month | −7.3 ± 7.0          | −8.5 ± 8.9             | −3.6 ± 8.1              | <0.0001  |
| ≥50% headache days rate           | 51.4%                | 66.5%                  | 36.8%                   | <0.0001  |
| ≥50% moderate-severe headache days rate | 54.2%              | 70.6%                  | 38.3%                   | <0.0001  |
| Conversion to episodic migraine   | 52.9%                | 68.0%                  | 38.3%                   | <0.0001  |
| ≥50% pain intensity reduction     | 35.8%                | 50.0%                  | 21.0%                   | <0.0001  |
| Acute treatment use (pills/month) | −24.9 ± 26.5         | −34.2 ± 52.7           | −14.1 ± 37.9            | <0.0001  |
| ≥50% acute treatment reduction (pills/month) | 60.4%            | 69.6%                  | 49.3%                   | <0.0001  |
| Conversion from medication overuse to non-medication overuse | 37.5% | 44.8% | 30.3% | 0.004 |
| ≥50% MIDAS score reduction rate   | 49.1%                | NA                     | NA                      | NA       |

*Responders were patients who presented a ≥50% improvement in MIDAS score after two cycles of OnabotulinumtoxinA. P-values are assessed between responders and non-responders. Unpaired t-test were used for quantitative variables and Pearson’s Chi-squared test with Yate’s continuity correction for dichotomous variables.
A sub-analysis of this group showed that those patients who had a ≥ 50% intensity reduction but did not experience ≥ 50% frequency improvement had a 62.8% chance of improvement in disability, with a mean MIDAS score reduction of 66.2 ± 69.6 points. Viceversa, this response probability is similar to the one seen in patients with ≥ 50% frequency reduction but poor effect on intensity (57.7%), with a mean reduction of 51.6 ± 54.6 points in MIDAS score. Although our data show a higher impact on disability when the improvement is driven by a decrease in intensity, the differences with the group which improves in frequency are not statistically significant. In this subset of patients with ≥ 50% intensity response, we did not find any demographical or clinical characteristic that predicted disability improvement.

Finally, a 35.0% of patients did not have a good response either in frequency or in intensity. In this group

**Table 3** Logistic regression model for ≥50% MIDAS score reduction rate

|                          | OR (95% CI)            | P-value |
|--------------------------|------------------------|---------|
| Headache days/month reduction | 0.944 (0.900–0.989)   | 0.016   |
| Moderate-severe headache days/month reduction | 0.981 (0.948–1.014)   | 0.259   |
| ≥ 50% headache days rate  | 0.863 (0.296–2.523)    | 0.785   |
| ≥ 50% moderate-severe headache days rate | 0.811 (0.798–1.348)   | 0.635   |
| Conversion to episodic migraine | 1.014 (0.490–3.742)   | 0.976   |
| ≥ 50% pain intensity reduction | 2.486 (1.422–4.392)   | 0.002   |
| Acute treatment use (pills/month) | 0.993 (0.982–1.001)   | 0.144   |
| ≥ 50% acute treatment reduction (pills/month) | 0.848 (0.417–1.689)   | 0.644   |
| Conversion to non-medication overuse | 1.073 (0.392–2.591)   | 0.814   |

Odds Ratio estimated from logistic regression analysis of the clinical outcomes associated to disability improvement. In bold are statistically significant outcomes from the model. The accuracy of the model (95% CI) in the testing set (n = 77 patients) was 0.64 (0.62–0.75), kappa = 0.30 and p-value = 0.015. OR Odds-ratio, CI Confidence Interval

**Fig. 1** Clinical outcomes that showed significant association with ≥50% MIDAS score reduction after 6 months of preventive treatment with OnabotulinumtoxinA. **a** shows response rate in frequency, intensity, and **b** co-variable frequency-intensity according to treatment response.
of patients, only 6.9% had ≥50% MIDAS improvement. When we analyzed this small group of patients, we observed that the disability improvement in this subgroup was associated with a higher decrease in the severe days whether there were not significant changes on headache frequency (severe/headache days in <50% MIDAS: ≥20.3% ± 19.7 vs. ≥50% MIDAS: ≥35.0 ± 34.99; p = 0.020), what also points to the influence of the intensity of headache.

Discussion

Migraine is considered the second most disabling neurological disorder in years lived with disability [16]. Preventive treatment in chronic migraine can help reduce headache frequency or attack intensity and improve a patient’s quality of life [17]. Our research wants to serve as a reflection on which outcome measures used in clinical trials are more likely to have an impact on the patient’s disability improvement, and consequently to assess treatment response in a real-life clinical setting.

We demonstrate in a clinical sample of patients with chronic migraine that, after 6 months of treatment with OnabotulinumtoxinA, headache frequency reduction is not the only outcome independently associated with MIDAS improvement but also pain intensity, and should be considered also as a major clinical outcome measure. This study shows that patients without a significant improvement in headache frequency but who have an improvement in headache intensity have a similar impact on their disability, measured with MIDAS, as those who improve in frequency. Our results are in line with other studies which have tried to determine the influence of headache intensity and frequency on headache-related disability, and showed that disability increases progressively with increasing headache intensity but no significant relationship was found between headache frequency and disability [18]. So, a preventive treatment that has an impact on the severity of the attacks, reduces the patient’s disability in the same way as a reduction of ≥50% or more in headache frequency.

Although headache intensity is also considered a secondary outcome measure to evaluate preventive treatment response in clinical trials as well as clinical practice [7, 19], the vast majority of clinical real-life published studies that evaluate OnabotulinumtoxinA treatment response in different conditions, do not include the evaluation of headache pain intensity [20]. Besides, current clinical treatment guidelines for migraine prevention, define response to treatment based only in headache frequency reduction [21–23], even recommending to stop treatment if the frequency does not decrease in patients. Based on our findings, if we consider our patient’s disability, both frequency and intensity should be evaluated and considered, as it is common to find patients who experience a clear beneficial effect from a preventive treatment with just an improvement in the intensity or severity of attacks and without a noticeable influence on headache frequency.

Although our data show the importance of headache severity on patient reduction in disability, we have to keep in mind that changes in other measures, or the add up of several minor changes in more than one outcome measure may lead to a relevant global effect on a patient’s disability and quality of life. Acute medication intake and its overuse, is also a highly clinically relevant outcome and, in some patients, could turn into a key aspect in chronic migraine prevention. Besides, in a clinical setting, physicians should respect patient’s preferences. Patient’s preferences for a migraine preventive therapy include effectiveness but also tolerability, speed of onset, formulation, dosing and cost [24, 25] that should also be re-evaluated when treatment response is assessed in order to provide the patient with an effective and well tolerated treatment.

This study has several strengths including the longitudinal study design with prospective data collection in a large and well characterized sample of migraine patients that were evaluated by headache experts. The main limitation is that only response to preventive treatment with OnabotulinumtoxinA has been evaluated in this study and therefore, all patients included suffered from chronic migraine. However, a unified sample has some advantages for this analysis since it is a standardized treatment at per-protocol established doses that is administered in the clinic, which ensures a high rate of therapeutic compliance. Despite its limitations, our data make us reflect about the probable validity of clinical trial endpoints as well as real-life outcome measures in order to properly reflect the impact in a patient’s disability with preventive treatments for chronic and probably episodic migraine. Moreover, in our opinion, future studies in chronic and episodic migraine should evaluate the response to oral as well as calcitonin gene related peptide monoclonal antibodies taking into consideration both changes in frequency and intensity of migraine.

A point that needs further discussion is the use of headache-related disability, measured by MIDAS scale, as a principal outcome measure. As clinicians, our main goal when we treat any headache patient should always be to minimize headache-related disability and its impact on quality of life. We consider that, despite its limitations, the MIDAS scale is a global, well-validated and widely-used measure of migraine-related disability [26, 27]. Indeed, the other widely used scale to assess headache-related disability is Headache Impact Test 6 or HIT-6 [28]. There is scarce comparative data on these two scales, showing a correlation between MIDAS and HIT-6 scores, especially for chronic migraine patients.
Compared to MIDAS, HIT-6 scale includes a more emotional and subjective evaluation of disability and appears to be more influenced by headache intensity while MIDAS score could be more influenced by frequency [30]. We also tested our findings using HIT-6 scale in a smaller sample (210 patients) and although there was also a statistically significant reduction of mean HIT-6 before and after treatment associated to frequency and intensity improvement, the mean change in the numerical score did not allow us to test the statistical model.

Conclusions
Intensity is as important as frequency when evaluating the improvement in disability in chronic migraine patients after preventive treatment with OnabotulinumtoxinA. A 50% reduction in headache frequency and intensity could equally and individually be considered as primary outcome measure. In future clinical preventive migraine treatment trials, we might consider the importance of reflecting the change not only in headache frequency but also in headache pain intensity as a primary outcome measure which is meaningful for patients, as it has an impact on their migraine related disability.

Abbreviations
AUC: Area Under the Curve; CI: Confidence Interval; CV: Cross Validation; HIT-6: Headache Impact Test 6; MIDAS: Migraine Disability Assessment Test; OR: Odds Ratio; ROC: Receiver Operating Characteristic Curve; SD: Standard Deviation

Acknowledgements
Not applicable.

Authors’ contributions
All authors made substantial contributions to conception and study design and data collection. VJG contributed to analysis and interpretation of data. MTF wrote first draft. MTF, VJG, AAR and PPR critically revised and finally approved the version to be published.

Funding
This study is not industry-sponsored. The authors disclose receipt of financial support from Allergan for publication fees for this article.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by Vall d’Hebron Ethics Committee. All patients gave their consent for data collection.

Consent for publication
All authors fully comply with and approve the version to be published.

Competing interests
Torres-Ferrus M has received honoraria as speaker for Allergan, Chiesi, Novartis and Lilly. Gallardo VJ reports no disclosures. Alpuente-Ruiz A has received honoraria as speaker for Allergan, Pozzo-Rosich P has received honoraria as a consultant and speaker for: Allergan, Almirall, Amgen, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Allergan, and has received funding for clinical trials from Alder, Electrocore, Eli Lilly, Novartis. She is a trustee member of the board of the International Headache Society, member of the Council of the European Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Neurologia, Frontiers of Neurology and Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of www.midolordeca-beza.org. Pozzo-Rosich P does not own stocks from any pharmaceutical company.

Received: 25 April 2020 Accepted: 6 July 2020
Published online: 11 July 2020

References
1. Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15(1):70–78
2. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 50(6):921–936
3. Matharu M, Halker R, Pozzo-Rosich P, DeGryse R, Manack Adams A, Aurora SK (2017) The impact of onabotulinumtoxin on severe headache days. PREEMPT 56-week pooled analysis. J Headache Pain 18(1):78
4. Caronna E, Gallardo VJ, Hernández-Beltrán N, Torres-Ferrus M, Pozzo-Rosich P (2018) OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse. Front Neurol 9:980
5. Battay AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW et al (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16(7):877–887
6. Ruggieri M (2014 May) The cost effectiveness of Boton in Italian patients with chronic migraine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(Suppl 1):45–47
7. Tassorelli C, Diener RC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 38(9):815–832
8. Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 33(9):629–808
9. Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia. 38(11):1–211
10. Pozzo-Rosich P, Ezpeleta D (2015) In: Pozzo-Rosich P, Ezpeleta D (eds) Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2015. 3. Guía oficial de práctica clínica en cefaleas, Luzan 5, Madrid
11. Diener HC, Dodick DW, Aurora SK, Turkel CC (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 30(7):894–814
12. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN et al (1999) An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology 53(5):988
13. Lipton RB, Stewart WF, Sawyer J, Edmeads J (2001) Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache. 41(9):854–861
14. Edmeads J, Láinez JM, Brandes JL, Schoenen J, Freitag F (2001) Potential of the migraine disability assessment (MIDAS) questionnaire as a public health initiative and in clinical practice. Neurology. 56(6 suppl 1):S29–S34
15. Masters-Israiov A, Robbins MS (2019) OnabotulinumtoxinA: an effective tool in the treatment of chronic migraine. Expert Rev Neurother 19(10):1753–1761
16. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388(10033):1545–1602
17. Sun-Edelstein C, Rapoport AM (2016) Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep 20(1):1
18. Magnusson JE, Becker WJ (2003) Migraine frequency and intensity: relationship with disability and psychological factors. Headache J Head Face Pain 43(10):1049–1059
19. Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozzo-Rosich P et al (2018) Guidelines on the use of onabotulinumtoxinA in chronic migraine: a
consensus statement from the European headache federation. J Headache Pain 19(1):91

20. Andreou AP, Trimboli M, Al-kaisy A, Murphy M, Fenech C, Smith T et al (2018) A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K., technology appraisal. Eur J Neurol 25(8):1069–1083

21. Evers S, Afra J, Frieze A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 16(9):968–981

22. National Institute for Health and Clinical Excellence (2016) Botulinum toxin type a for the prevention of headaches in adults with chronic migraine, pp 1–50

23. Loder E, Burch R, Rizzoli P (2012) The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 52(6):930–945

24. Peres MFP, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N et al (2007) Patients’ preference for migraine preventive therapy. Headache. 47(4):540–545

25. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 37(5):470–485

26. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 88(1):41–52

27. Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(suppl 1):S20–S28

28. Kosinski M, Bayliss MS, Bjorner JB, Ware JEJ, Garber WH, Batenhurst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Cephalalgia. 28(1):963–974

29. Magnoux E, Freeman MA, Zlotnik G (2008) MIDAS and HIT-6 French translation: reliability and correlation between tests. Cephalalgia. 28(1):26–34

30. Sauro KM, Rose MS, Becker WJ, Christie SN, Giammarco R, Mackie GF et al (2010) HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache. 50(3):383–395

31. Ghorbani A, Chitsaz A (2011) Comparison of validity and reliability of the migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol 10(3–4):39–42

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions